litlas
Log inCreate account

Marcin Kowanetz

Active 2002–2024

54
Papers
28,710
Citations
48
h-index
51
i10-index

Citations

Citations per year for Marcin Kowanetz1995: 1 citations2000: 1 citations2001: 2 citations2003: 19 citations2004: 26 citations2005: 38 citations2006: 58 citations2007: 62 citations2008: 48 citations2009: 79 citations2010: 68 citations2011: 90 citations2012: 74 citations2013: 89 citations2014: 150 citations2015: 282 citations2016: 424 citations2017: 508 citations2018: 641 citations2019: 1,915 citations2020: 2,285 citations2021: 2,011 citations2022: 1,431 citations2023: 952 citations2024: 1,195 citations2025: 506 citations2026: 10 citations1996–1999: no citations, so these years are not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,630 citing papers, 23.5% of this breakdownChina: 2,766 citing papers, 17.9% of this breakdownJapan: 824 citing papers, 5.4% of this breakdownItaly: 805 citing papers, 5.2% of this breakdownFrance: 748 citing papers, 4.9% of this breakdownUnited Kingdom: 681 citing papers, 4.4% of this breakdownGermany: 680 citing papers, 4.4% of this breakdownSpain: 507 citing papers, 3.3% of this breakdownSouth Korea: 407 citing papers, 2.6% of this breakdownSwitzerland: 388 citing papers, 2.5% of this breakdownCanada: 387 citing papers, 2.5% of this breakdownAustralia: 386 citing papers, 2.5% of this breakdown
0%23.5%Other 20.9%

Institutions

Fields

  • Medicine71.9%
  • Biochemistry, Genetics and Molecular Biology16.2%
  • Immunology and Microbiology9%
  • Engineering1%
  • Neuroscience0.6%
  • Materials Science0.3%
  • Other1%

Topics

  • Cancer Immunotherapy and Biomarkers20.5%
  • Lung Cancer Treatments and Mutations6.8%
  • Immunotherapy and Immune Responses6.1%
  • Lung Cancer Research Studies4.3%
  • CAR-T cell therapy research3.8%
  • Immune cells in cancer3.4%
  • Other55.1%

Coauthors

All papers

Open in search
  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Authors: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck - New England Journal of Medicine 2018 cited by 3,753

  2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Authors: Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi - Nature 2014 cited by 5,302

  3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    Authors: Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara - The Lancet 2016 cited by 4,780

  4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

    Authors: Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo - The Lancet Oncology 2019 cited by 1,681

  5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

    Authors: Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer - The Lancet 2016 cited by 2,803

  6. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

    Authors: Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski, Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski - The Lancet Respiratory Medicine 2019 cited by 939

  7. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

    Authors: Maud Mayoux, Andreas Roller, Vesna Pulko, Stefano Sammicheli, Stanford Chen, Eva Sum, Christian Jöst, Marieke F. Fransen, Regula B. Buser, Marcin Kowanetz, Karolin Rommel, Ines Matos, Sara Colombetti, Anton Belousov, Vaios Karanikas, Ferry Ossendorp, Priti S. Hegde, Daniel S. Chen, Pablo Umaña, Mario Perro, Christian Klein, Wei Xu - Science Translational Medicine 2020 cited by 380

  8. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    Authors: David R. Gandara, Sarah Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Doron Lipson, Jacob Silterra, Lukas C. Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Alan Sandler, Marcus Ballinger, David Fabrizio, Tony Mok, David S. Shames - Nature Medicine 2018 cited by 1,195

  9. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

    Authors: Shelley E. Ackerman, Cecelia I. Pearson, Joshua D. Gregorio, Joseph C. González, Justin A. Kenkel, Felix J. Hartmann, Angela Luo, Po Y. Ho, Heidi Leblanc, Lisa K. Blum, Samuel C. Kimmey, Andrew Luo, Murray L. Nguyen, Jason C. Paik, Lauren Y. Sheu, Benjamin Ackerman, Arthur Lee, Hai Li, Jennifer Melrose, Richard Laura, Vishnu C. Ramani, Karla A. Henning, David Y. Jackson, Brian S. Safina, Grant Yonehiro, Bruce H. Devens, Yaron Carmi, Steven J. Chapin, Sean C. Bendall, Marcin Kowanetz, David Dornan, Edgar G. Engleman, Michael N. Alonso - Nature Cancer 2020 cited by 203

  10. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

    Authors: Marcin Kowanetz, Xiumin Wu, John Lee, Martha Tan, Thijs J. Hagenbeek, Xueping Qu, Lanlan Yu, Jed Ross, Nina Korsisaari, Tim C. Cao, Hani Bou-Reslan, Dara Kallop, Robby M. Weimer, Mary J. C. Ludlam, Joshua S. Kaminker, Zora Modrušan, Nicholas van Bruggen, Franklin Peale, Richard A.D. Carano, Y. Gloria Meng, Napoleone Ferrara - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 665

  11. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

    Authors: Romain Banchereau, Avantika S. Chitre, Alexis Scherl, Thomas D. Wu, Namrata S. Patil, Patrícia de Almeida, Edward E. Kadel, Shravan Madireddi, Amelia Au‐Yeung, Chikara Takahashi, Ying‐Jiun Chen, Zora Modrušan, Jacqueline McBride, Rhea Nersesian, Ehab A. ElGabry, Mark D. Robida, Jeffrey Hung, Marcin Kowanetz, Wei Zou, Mark L. McCleland, Patrick Caplazi, Shadi Toghi Eshgi, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, W. Rodney Mathews, Thomas Powles, Sanjeev Mariathasan, Jane L. Grogan, William O’Gorman - Journal for ImmunoTherapy of Cancer 2021 cited by 147

  12. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

    Authors: Solange Peters, Scott Gettinger, Melissa L. Johnson, Pasi A. Jänne, Marina Chiara Garassino, Daniel C. Christoph, Chee‐Keong Toh, Naiyer A. Rizvi, Jamie E. Chaft, Enric Carcereny, Jyoti D. Patel, Laura Q.M. Chow, Marianna Koczywas, Cheryl Ho, Martin Früh, Michel M. van den Heuvel, J. Rothenstein, Martin Reck, Luis Paz‐Ares, Frances A. Shepherd, Takayasu Kurata, Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, Alan Sandler, Enriqueta Felip - Journal of Clinical Oncology 2017 cited by 419

  13. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

    Authors: Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R. Gandara, Santiago Ponce Aix, Ji‐Youn Han, Shirish M. Gadgeel, Toyoaki Hida, Diego Cortinovis, Manuel Cobo, Dariusz M. Kowalski, Filippo de Marinis, Mayank Gandhi, Bradford J. Danner, Christina Matheny, Marcin Kowanetz, Pei He, Federico Felizzi, Hina Patel, Alan Sandler, Marcus Ballinger, Fabrice Barlési - Journal of Thoracic Oncology 2018 cited by 261

  14. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

    Authors: Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 cited by 239

  15. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

    Authors: Marius Ilié, Edith Szafer‐Glusman, Véronique Hofman, Emmanuel Chamorey, Salomé Lalvée, Éric Selva, Sylvie Leroy, Charles‐Hugo Marquette, Marcin Kowanetz, P. Hedge, Elizabeth A. Punnoose, Paul Hofman - Annals of Oncology 2017 cited by 202

  16. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

    Authors: Michael Fehlings, Suchit Jhunjhunwala, Marcin Kowanetz, William O’Gorman, Priti S. Hegde, Hermi Sumatoh, Boon Heng Lee, Alessandra Nardin, Étienne Becht, Susan Flynn, Marcus Ballinger, Evan W. Newell, Mahesh Yadav - Journal for ImmunoTherapy of Cancer 2019 cited by 86

  17. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

    Authors: Farbod Shojaei, Xiumin Wu, Xueping Qu, Marcin Kowanetz, Lanlan Yu, Martha Tan, Y. Gloria Meng, Napoleone Ferrara - National Academy of Sciences, Proceedings of the National Academy of Sciences 2009 cited by 469

  18. Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma

    Authors: Benjamin Solomon, Richard J. Young, Mathias Bressel, Damien Urban, Shona Hendry, Alesha A. Thai, Christopher Angel, Afaf Haddad, Marcin Kowanetz, Tsien Fua, June Corry, Stephen B. Fox, Danny Rischin - Cancer Immunology Research 2018 cited by 127

  19. TGF-β and the Smad Signaling Pathway Support Transcriptomic Reprogramming during Epithelial-Mesenchymal Cell Transition

    Authors: Ulrich Valcourt, Marcin Kowanetz, Hideki Niimi, Carl‐Henrik Heldin, Aristidis Moustakas - Molecular Biology of the Cell 2005 cited by 589

  20. Stable Expression of Angiopoietin-1 and Other Markers by Cultured Pericytes: Phenotypic Similarities to a Subpopulation of Cells in Maturing Vessels During Later Stages of Angiogenesis In Vivo

    Authors: Christian Sundberg, Marcin Kowanetz, Lawrence F. Brown, Michael Detmar, Harold F. Dvorak - Laboratory Investigation 2002 cited by 251

  21. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

    Authors: Bharathi Vennapusa, Brian M. Baker, Marcin Kowanetz, Jennifer Boone, Ina Menzl, Jean‐Marie Bruey, Gregg Fine, Sanjeev Mariathasan, Ian McCaffery, Simonetta Mocci, Sandra Rost, Dustin Smith, Eslie Dennis, Szu‐Yu Tang, Bita Damadzadeh, Espen J. Walker, Priti S. Hegde, J. Andrew Williams, Hartmut Koeppen, Zachary Boyd - Applied immunohistochemistry & molecular morphology 2018 cited by 189

  22. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

    Authors: David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi - Journal of Thoracic Oncology 2018 cited by 172

  23. Immune profiles in primary squamous cell carcinoma of the head and neck

    Authors: Vassiliki Saloura, Evgeny Izumchenko, Zhixiang Zuo, Riyue Bao, Michael Korzinkin, Ivan V. Ozerov, Alex Zhavoronkov, David Sidransky, Atul Bedi, Mohammad Obaidul Hoque, Hartmut Koeppen, Michaela K. Keck, Arun Khattri, Nyall R. London, Nikita Kotlov, Aiman Fatima, Theodore Vougiouklakis, Yusuke Nakamura, Mark W. Lingen, Nishant Agrawal, Peter A. Savage, Stephen J. Kron, Justin Kline, Marcin Kowanetz, Tanguy Y. Seiwert - Oral Oncology 2019 cited by 73

  24. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment

    Authors: Vernon T. Phan, Xiumin Wu, Jason Cheng, Rebecca X. Sheng, Alicia S. Chung, Guanglei Zhuang, Christopher Tran, Qinghua Song, Marcin Kowanetz, Amy Sambrone, Martha Tan, Y. Gloria Meng, Erica L. Jackson, Franklin Peale, Melissa R. Junttila, Napoleone Ferrara - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 115